Crinetics Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CRNX and other ETFs, options, and stocks.

About CRNX

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. 

CEO
Scott R. Struthers
CEOScott R. Struthers
Employees
437
Employees437
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
2008
Founded2008
Employees
437
Employees437

CRNX Key Statistics

Market cap
4.10B
Market cap4.10B
Price-Earnings ratio
-10.13
Price-Earnings ratio-10.13
Dividend yield
Dividend yield
Average volume
2.53M
Average volume2.53M
High today
$42.77
High today$42.77
Low today
$41.26
Low today$41.26
Open price
$41.80
Open price$41.80
Volume
798.81K
Volume798.81K
52 Week high
$62.53
52 Week high$62.53
52 Week low
$24.10
52 Week low$24.10

CRNX News

Simply Wall St 3d
Crinetics Pharmaceuticals Shares Swing After Data on Paltusotine and Valuation Metrics Scrutinized

If you have been eyeing shares of Crinetics Pharmaceuticals lately, you are not alone. Investors are wrestling with what to make of this intriguing biotech stoc...

Crinetics Pharmaceuticals Shares Swing After Data on Paltusotine and Valuation Metrics Scrutinized

Analyst ratings

88%

of 17 ratings
Buy
88.2%
Hold
11.8%
Sell
0%

People also own

Based on the portfolios of people who own CRNX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.